Tagrisso® Cost Disrupting Lung Cancer Treatment? How To Get A Low-Cost Osimertinib Alternative Globally

Summary - Tagrisso® (osimertinib) is a targeted medicine for EGFR-mutated non-small cell lung cancer, but its US price adds up to thousands of dollars a month. No affordable alternative or generic is available in many countries. This blog covers how MedsPartner helps patients worlwide access an affordable Osimertinib variant - manufactured by a EU GMP certified manufacturer- safely and legally.

Non-small cell lung cancer (NSCLC) accounts for around 85% of all lung cancer diagnoses globally. Among patients with advanced NSCLC, many carry EGFR mutations that drive their cancer - and for these patients, targeted therapy improves outcomes. Osimertinib (Tagrisso®) is now the first-line standard of care for EGFR-mutated advanced NSCLC, with clinical trial data showing promising results. But one hurdle still remains for thousands of patients - the high cost of the medicine.

In the US, branded Tagrisso® costs approximately USD 17,746 per month, and no affordable version is currently available domestically. Similar scenarios exist in many parts of the world. Through MedsPartner, patients can access an affordable Osimertinib variant sourced from an EU GMP-approved manufacturer in Sweden. Here is how patients in various geographies, including USA, UK, Australia, New Zealand and 45+ other nations can access it.

What is Osimertinib’s mechanism of action? How does it help lung cancer patients?

Osimertinib is an oral medication belonging to a class of medicines called EGFR tyrosine kinase inhibitors (TKIs). It is approved for:

• First-line treatment of metastatic NSCLC in adults with EGFR mutations
• Adjuvant therapy for early stage NSCLC following complete tumour removal

In EGFR-mutated lung cancer, a fault in the EGFR protein keeps sending signals to cancer cells - telling them to keep growing. Osimertinib works by blocking these growth signals, effectively switching off the driver of the cancer. Unlike older EGFR medicines, Osimertinib can continue to work even when the cancer develops common forms of resistance seen after earlier treatment.

Osimertinib also crosses the blood-brain barrier - crucial because EGFR-mutated NSCLC has a relatively high rate of spreading to the brain.

Large clinical studies have shown that Osimertinib helps more patients respond to treatment and keeps the cancer under control for longer than older EGFR-targeted medicines. It has also improved overall survival for many patients with advanced EGFR-positive lung cancer. It has also been shown to reduce the risk of cancer returning after surgery as an adjuvant therapy. 

Why is Tagrisso® so costly in the USA & other countries?

AstraZeneca developed Osimertinib specifically to address EGFR-mutated NSCLC. The high cost of Tagrisso® was set to compensate for high clinical value, years of R&D, clinical trials and marketing. With no approved generic equivalent available in the US, there is no price competition to bring costs down.

For most patients without insurance, the high monthly cost is impossible to afford. Even with insurance, Tagrisso® falls under specialty oncology tiers with coinsurance of 20-30%, leaving patients with monthly costs running into thousands of dollars before deductibles. In other countries, pricing varies by market and health system coverage - but in many regions, branded Tagrisso® at international pricing is simply unaffordable without subsidy.

In these circumstances, patients may source an affordable Osimertinib variant through compliant personal importation via MedsPartner.

How much can I save on Tagrisso® cost by switching to MedsPartner’s Osimertinib variant?

Standard dosing of Tagrisso® is 80mg once daily or 30 tablets per month. In the US, branded Tagrisso® is the only available option, which is priced very high. MedsPartner offers an affordable variant at a significantly lower price.

MedsPartner's Osimertinib variant is sourced from an EU GMP-approved manufacturer in Sweden - made as per the same regulatory standards that governs medicines sold across the European Union. Pricing is available on enquiry; contact the MedsPartner team or visit the product page for current details.

Is international personal import of an Osimertinib variant legal?

Yes. Several countries permit patients to import essential medicines when local options are too expensive or unavailable. These medicines should be for their own personal use, and can be imported in limited quantities. The patient must have a valid prescription and other documents as per their country’s regulations. MedsPartner takes care of shipping in line with each country’s personal import guidelines. We support patients in understanding their region’s personal import laws and make sure that each order is processed compliantly, removing unnecessary overheads for the patient. We have 9+ years of experience in facilitating personal imports of medicines to 45+ countries.

How can I place an order for Osimertinib on MedsPartner?

Start by reviewing product details on the MedsPartner Osimertinib product page & submit an order request. Once your prescription is received, the team reviews it, checks the personal import requirements for your country, and lets you know the pricing and any additional documents needed.

After all documents & payment are received, your medicine is sourced from the EU GMP-approved manufacturer in Sweden & dispatched to your doorstep as per your country’s regulations. Most shipments reach customers within 1-2 weeks through international courier.

Case Study - Supplying affordable Osimertinib to a patient in Colombia

Sofia, a 57-year-old in Bogotá, was diagnosed with metastatic NSCLC with EGFR exon 19 deletion. Her oncologist recommended Osimertinib as first-line treatment. Private pharmacy pricing for branded Tagrisso® in Colombia was beyond her financial means.

A fellow patient at her clinic suggested exploring personal import options and shared his personal experience with MedsPartner. She reached out to our team over email and we guided her through the whole process. After reviewing all necessary documents, we sourced affordable Osimertinib from our vetted manufacturer in Sweden & shipped it to Bogotá. For Sofia, this made the cost of the treatment much more manageable, allowing her to start and continue therapy without any breaks.

FAQs on Tagrisso® cost & affordable Osimertinib alternatives

Q1. Is the Osimertinib variant from MedsPartner as effective as branded Tagrisso®?

A - The Osimertinib variant offered by MedsPartner contains the same active ingredient as branded Tagrisso® & is manufactured in Sweden by an EU GMP-approved facility, meeting the quality standards required for medicines across the European Union. This ensures that the medicine offers similar benefits as Tagrisso®.

Q2. How much can I save by accessing Osimertinib through MedsPartner?

A - Branded Tagrisso® costs approximately USD 17,750 per month in the US for the standard 80mg daily dose. MedsPartner's Osimertinib variant is available at a significantly lower cost. Visit the product page or contact the team for current pricing.

Q3. Is it legal to import an Osimertinib variant for personal use?

A - In most countries, yes. Personal import of essential or life-saving medicines is permitted for patients with a valid prescription & in limited quantities meant for personal use. MedsPartner's team can explain how this works in your country & process your order as per your country’s personal import laws. More information is available here.

Q4. How can I trust the quality of the Osimertinib variant from MedsPartner?

A - The Osimertinib variant MedsPartner supplies is manufactured in Sweden by a EU GMP certified facility. Every shipment includes manufacturer details, expiry information & batch numbers, so that you know the exact source of your medicine. MedsPartner has successfully shipped over 30,000+ orders over 9+ years, and has a 4.8-star rating on TrustPilot that demonstrates their quality.

Q5. I am a doctor. How can I support my patients in getting affordable Osimertinib?

A - Email support@medspartner.com with your patient's info and prescription. Our team will reach out to your patient directly, verify all documents & arrange shipment to their address in line with the patient's local personal import laws.

Q6. What are the common side effects of Tagrisso® / osimertinib?

A - Common side effects of osimertinib include diarrhea, rash, dry skin, nail changes, and mouth sores. Some patients also experience reduced blood cell counts & elevated liver enzymes, which are monitored with periodic blood tests. Rare but more serious effects include lung inflammation, heart rhythm changes, and cardiac toxicity - which will be monitored by your doctor. Contact your doctor promptly if you develop worsening breathlessness, chest pain, or significant skin reactions.

Q7. What is the step-by-step process for ordering through MedsPartner?

A - Visit the Osimertinib product page & submit an order request - no payment is required at this stage. Upload your valid prescription, and MedsPartner checks your country's import requirements & shares the document requirements and pricing details. Once all the documents are verified & payment is made, your medicine is sourced from the EU GMP facility in Sweden & shipped to your address with all required customs paperwork.

Q8. What if my insurance denies coverage or demands a high co-pay for Tagrisso®?

A - Ask your oncologist to submit a prior authorisation appeal supported by your EGFR mutation test results, staging, and clinical justification for osimertinib. AstraZeneca's Access 360 programme offers eligible commercially insured patients savings on copay for Tagrisso®. The AZ&Me Prescription Savings Program provides free medicine for uninsured patients who qualify. If neither option resolves the cost, MedsPartner's affordable variant allows treatment to continue without price hurdles.

Q9. Are there other support options for accessing Tagrisso® at a lower cost?

A - The Patient Access Network (PAN) Foundation provides copay assistance for eligible insured patients in the US, and AstraZeneca's own AZ&Me programme covers uninsured patients who meet income requirements. But not everyone meets the eligibility criteria or receives adequate support. For patients who do not qualify or who need higher savings, MedsPartner's personal import pathway for low-cost alternatives provides a suitable option.

Affordable lung cancer treatment options exist when Tagrisso® is too costly

Tagrisso® is one of the most important targeted therapies in lung cancer - but at nearly USD 17,800 per month with no domestic generic available in the US, consistent access is not affordable for many patients. MedsPartner's affordable Osimertinib variant - manufactured in Sweden as per EU GMP standards - gives patients a way to access their prescribed treatment without the full burden of branded pricing.

Need more info on personal importation? Write to us to learn how to access the affordable Osimertinib variant safely & legally in your country, or visit the Osimertinib product page to get started.

About the Author - Atul Goyal combines operational insight with a strong understanding of global healthcare systems - honed through years of managing complex pharmaceutical supply chains. At MedsPartner - he leads efforts to streamline international medicine deliveries, balancing efficiency, compliance & patient affordability. His experience spans logistics, pricing strategy & regulatory frameworks - enabling him to navigate the evolving landscape of global medicine access with both precision and empathy.